An atypical pulmonary carcinoid tumor with a long-lasting response to octreotide: a case report
Mao Sasamotoa,b Yuji Shibataa Hibiki Udagawaa Tokiko Nakaic Hiroki Ninomiyab Koichi Gotoa
aDepartment of Thoracic Oncology, National Cancer Center Hospital East
bDepartment of Respiratory Medicine, Kobari General Hospital
cDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital East
In 20XX-8, a 41-year-old female patient was diagnosed with an atypical pulmonary carcinoid tumor and underwent middle lobectomy of the right lung and mediastinal lymph node dissection (pT2bN1M0). After that, she underwent surgical resection for metastatic recurrences three times. In the year 20XX, multiple enlarged cervical lymph nodes appeared and an accumulation of indium-111 labeled pentetreotide was observed in the same region by somatostatin receptor scintigraphy (SRS). It was judged to be an unresectable postoperative recurrence, and treatment with octreotide was started. The tumor shrank markedly, and the response has been sustained for more than 5 years. Octreotide has low toxicity and may be a useful treatment option, especially in SRS-positive patients.
Pulmonary carcinoid (PC) Atypical carcinoid (AC) Octreotide Somatostatin receptor scintigraphy (SRS)
Received 2 Feb 2022 / Accepted 2 Jun 2022
AJRS, 11(5): 315-320, 2022